Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$7.23 +1.7%	$6.30	$3.93 ▼ $7.54	$364.59M	1.55	710,270 shs	850,820 shs
ARCT Arcturus Therapeutics	$18.51 +5.9%	$14.08	$8.04 ▼ $25.88	$474.66M	2.26	742,476 shs	505,286 shs
CRVS Corvus Pharmaceuticals	$5.55 +4.9%	$4.37	$2.54 ▼ $10.00	$394.18M	0.42	466,447 shs	619,189 shs
QNTM Quantum Biopharma	$18.08 +0.2%	$22.59	$2.70 ▼ $38.25	$52.48M	0.71	190,791 shs	76,613 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	+1.69%	+1.40%	+7.75%	+12.62%	+37.98%
ARCT Arcturus Therapeutics	+5.89%	-4.98%	+19.81%	+51.72%	-15.40%
CRVS Corvus Pharmaceuticals	+4.91%	+2.21%	+18.84%	+59.03%	+33.73%
QNTM Quantum Biopharma	+0.17%	-19.47%	-20.14%	+56.54%	+1,807,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABEO Abeona Therapeutics	4.4467 of 5 stars	3.5	2.0	0.0	4.5	2.5	2.5	1.3
ARCT Arcturus Therapeutics	3.1409 of 5 stars	3.5	2.0	0.0	0.0	3.8	2.5	0.6
CRVS Corvus Pharmaceuticals	2.9928 of 5 stars	3.5	2.0	0.0	0.0	2.4	3.3	0.6
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	3.00	Buy	$19.50	169.71% Upside
ARCT Arcturus Therapeutics	3.00	Buy	$50.57	173.21% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	170.27% Upside
QNTM Quantum Biopharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest QNTM, ARCT, CRVS, and ABEO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	ARCT Arcturus Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$63.00 ➝ $54.00
8/18/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/15/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$19.00 ➝ $20.00
8/12/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$47.00 ➝ $49.00
8/12/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $42.00
7/14/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$32.00 ➝ $35.00
6/18/2025	QNTM Quantum Biopharma	Singular Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
6/2/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$19.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$3.50M	105.93	N/A	N/A	$3.19 per share	2.27
ARCT Arcturus Therapeutics	$152.31M	3.30	N/A	N/A	$8.51 per share	2.18
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$1.08 per share	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	$0.70 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	-$63.73M	$0.70	10.33	N/A	N/A	N/A	89.05%	45.64%	N/A
ARCT Arcturus Therapeutics	-$80.94M	-$2.23	N/A	N/A	N/A	-49.26%	-24.87%	-17.75%	11/6/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$62.29M	-$1.01	N/A	N/A	N/A	N/A	-28.61%	-18.05%	N/A
QNTM Quantum Biopharma	-$14.20M	-$14.02	N/A	N/A	N/A	N/A	-270.22%	-131.87%	11/10/2025 (Estimated)

Latest QNTM, ARCT, CRVS, and ABEO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ABEO Abeona Therapeutics	-$0.39	$1.71	+$2.10	$1.71	$21.71 million	$0.40 million
8/11/2025	Q2 2025	ARCT Arcturus Therapeutics	-$1.11	-$0.34	+$0.77	-$0.34	$17.64 million	$28.30 million
8/7/2025	Q2 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.10	+$0.03	-$0.10	N/A	N/A
8/6/2025	Q2 2025	QNTM Quantum Biopharma	-$0.17	-$3.23	-$3.06	-$3.23	$2.89 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.09	6.73	4.90
ARCT Arcturus Therapeutics	N/A	5.90	5.90
CRVS Corvus Pharmaceuticals	N/A	8.91	8.91
QNTM Quantum Biopharma	N/A	0.78	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
ARCT Arcturus Therapeutics	94.54%
CRVS Corvus Pharmaceuticals	46.64%
QNTM Quantum Biopharma	1.24%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	6.90%
ARCT Arcturus Therapeutics	16.60%
CRVS Corvus Pharmaceuticals	28.50%
QNTM Quantum Biopharma	8.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	90	51.28 million	47.74 million	Optionable
ARCT Arcturus Therapeutics	180	27.16 million	22.65 million	Optionable
CRVS Corvus Pharmaceuticals	30	74.51 million	53.28 million	Optionable
QNTM Quantum Biopharma	N/A	2.91 million	2.66 million	N/A

QNTM, ARCT, CRVS, and ABEO Headlines

Recent News About These Companies

Quantum Group announces corporate updates

August 21 at 12:46 PM | msn.com

Quantum BioPharma Announces Update to Previously Announced Private Placement

August 11, 2025 | newsfilecorp.comN

Why Is Quantum BioPharma In The News Today? Here’s An Important Update On Its Multiple Sclerosis Investigational Drug

August 11, 2025 | msn.com

Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial

August 11, 2025 | globenewswire.com

Quantum BioPharma Reports Positive Phase 1 Results for MS Drug Lucid-MS

August 9, 2025 | theglobeandmail.com

Quantum BioPharma Pursues Legal Action Over Alleged Stock Manipulation

August 9, 2025 | theglobeandmail.com

Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients

August 8, 2025 | globenewswire.com

Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt

August 7, 2025 | globenewswire.com

Quantum Biopharma (QNTM) to Release Earnings on Wednesday

August 7, 2025 | marketbeat.com

Quantum BioPharma stock falls after clinical trial report release

August 5, 2025 | investing.com

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)

August 5, 2025 | globenewswire.com

Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing

August 4, 2025 | globenewswire.com

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO

July 31, 2025 | globenewswire.com

Quantum BioPharma Makes Strategic Investment in GameStop

July 24, 2025 | theglobeandmail.com

Quantum BioPharma purchases 2,000 shares of GameStop

July 22, 2025 | msn.com

Quantum BioPharma stock falls after GameStop share purchase

July 22, 2025 | investing.com

Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom - Morningstar

July 9, 2025 | morningstar.comM

Quantum BioPharma Ltd. (QNTM) - Yahoo Finance

July 9, 2025 | finance.yahoo.com

Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom

July 8, 2025 | finance.yahoo.com

QNTM - Quantum BioPharma Ltd Ordinary Shares - Morningstar

July 3, 2025 | morningstar.comM

Quantum BioPharma Announces Private Placement - The Manila Times

June 29, 2025 | manilatimes.netM

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM, ARCT, CRVS, and ABEO Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$7.23 +0.12 (+1.69%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.21 -0.02 (-0.28%)

As of 08/22/2025 07:53 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Arcturus Therapeutics NASDAQ:ARCT

$18.51 +1.03 (+5.89%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$18.16 -0.36 (-1.92%)

As of 08/22/2025 06:59 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Corvus Pharmaceuticals NASDAQ:CRVS

$5.55 +0.26 (+4.91%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.50 -0.05 (-0.90%)

As of 08/22/2025 06:39 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Quantum Biopharma NASDAQ:QNTM

$18.08 +0.03 (+0.17%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$18.74 +0.66 (+3.62%)

As of 08/22/2025 07:58 PM Eastern

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time